Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Vemurafenib

Abstract

In August 2011 vemurafenib (Zelboraf; Daiichi Sankyo/Roche), an inhibitor of BRAF kinase, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with unresectable or metastatic melanoma with the BRAFV600E mutation.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: RAF inhibition.

References

  1. 1

    Garbe, C. et al. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 16, 5–24 (2011).

    CAS  Article  Google Scholar 

  2. 2

    Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).

    CAS  Article  Google Scholar 

  3. 3

    Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949–954 (2002).

    CAS  Article  Google Scholar 

  4. 4

    Tsai, J. et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl Acad. Sci. USA 105, 3041–3046 (2008).

    CAS  Article  Google Scholar 

  5. 5

    Bollag, G. et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596–599 (2010).

    CAS  Article  Google Scholar 

  6. 6

    US Food and Drug Administration. FDA labeling information — Zelboraf. FDA website [online], (2011).

  7. 7

    Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809–819 (2010).

    CAS  Article  Google Scholar 

  8. 8

    Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507–2516 (2011).

    CAS  Article  Google Scholar 

  9. 9

    Boni, A. et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 70, 5213–5219 (2010).

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding authors

Correspondence to Keith. T Flaherty, Uma Yasothan or Peter Kirkpatrick.

Ethics declarations

Competing interests

Keith Flaherty has served on the scientific advisory board for Genentech/Roche.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Flaherty, K., Yasothan, U. & Kirkpatrick, P. Vemurafenib. Nat Rev Drug Discov 10, 811–812 (2011). https://doi.org/10.1038/nrd3579

Download citation

Further reading

Search

Quick links